MOD GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The suit also alleged that Theranos had misled company directors about its practices concerning laboratory testing and that it had secretly bought lab equipment to run fake demonstrations. On May 1, 2017, Theranos announced that it had reached an undisclosed settlement with Partner Fund Management LP (PFM). Theranos's General Counsel, David Taylor, stated: "Theranos is pleased to have resolved both lawsuits with PFM. Although we are confident that we would have prevailed at trial, resolution of these two cases allows our tender offer to go forward and enables us to return our focus where it belongs, which is on executing our business plans and delivering value for our shareholders." In April 2017, Theranos reached a settlement with CMS agreeing to stay out of the blood-testing business for at least two years in exchange for reduced penalties, and signed a consent decree with Arizona Attorney General Mark Brnovich over violations of the Arizona Consumer Fraud Act. Alleged violations included false advertisement and inaccurate blood testing. Theranos agreed to refund $4.65 million to the state's residents for Theranos blood testing services, providing a refund to every resident who had received a test, regardless of whether the test results were voided or corrected. In August 2017, Theranos announced it had reached a settlement with Walgreens. In December 2017, Fortress Investment Group, a wholly owned company of Softbank Group, loaned $100 million to Theranos for 4% of the company.
=== Discontinued === Alprazolam inhalation (AZ-002; FNP-002; Staccato® alprazolam; STAP-001; UCB-7538) – GABAA receptor positive allosteric modulator and benzodiazepine [7] Alprazolam intranasal (Panistat) – GABAA receptor positive allosteric modulator and benzodiazepine [8] BTG-1640 (ABIO-08/01; ABIO-0801) – undefined mechanism of action [9] Eglumetad (Eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist [10] JNJ-19567470 (CRA-5626; R-317573) – corticotropin releasing factor receptor 1 (CRF1R) antagonist [11] Nefazodone (BMY-13754; Dutonin; MJ-13754; MS-13754; Nefadar; Serzone) – serotonin 5-HT1A receptor ligand, serotonin 5-HT2A and 5-HT2C receptor antagonist, α1- and α2-adrenergic receptor antagonist, weak serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), and other actions [12] Xenon (NBTX-001) – ionotropic glutamate NMDA receptor antagonist [13]
=== Lung toxicity === Pulmonary toxicity, or toxicity to lungs, is a serious complication associated with sirolimus therapy, especially in the case of lung transplants. The mechanism of the interstitial pneumonitis caused by sirolimus and other macrolide mTOR inhibitors is unclear, and may have nothing to do with the mTOR pathway. The interstitial pneumonitis is not dose-dependent, but is more common in patients with underlying lung disease.
== Medical characterization of gender variance == Gender variance is defined in medical literature as "gender identity, expression, or behavior that falls outside of culturally defined norms associated with a specific gender". For centuries, gender variance was seen by medicine as a pathology. The World Health Organization identified gender dysphoria as a mental disorder in the International Classification of Diseases (ICD) until 2018. Gender dysphoria was also listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) of the American Psychiatric Association, where it was previously called "transsexualism" and "gender identity disorder". In 2018, the ICD-11 included the term "gender incongruence" as "marked and persistent incongruence between an individual's experienced gender and the assigned sex", where gender variant behaviour and preferences do not necessarily imply a medical diagnosis. However, the difference between "gender dysphoria" and "gender incongruence" is not always clear in the medical literature. Some studies posit that treating gender variance as a medical condition has negative effects on the health of transgender people and claim that assumptions of coexisting psychiatric symptoms should be avoided. Other studies argue that gender incongruence diagnosis may be important and even positive for transgender people at the individual and social level.
== Departments == Division of Basic Medical Sciences I Department of Biochemistry Department of General Biology Department of Medical Physics Division of Basic Medical Sciences II Department of Anatomy Department of General Pharmacology Department of Physiology Division of Clinical Laboratories Department of Microbiology Department of Nuclear Medicine Department of Pathology Department of Public Health Department of Radiology Division of Internal Medicine Ι Department of Internal Medicine Division of Paediatrics & Obstetrics – Gynaecology Department of Obstetrics - Gynecology Department of Paediatric Surgery Department of Paediatrics Division of Surgery Department of Anaesthesiology and Intensive Care Department of Cardiothoracic Surgery Department of Neurosurgery Department of Ophthalmology Department of Orthopaedics Department of Otorhinolaryngology Department of Surgery Department of Urology Department of Vascular Surgery
Sources: en.wikipedia.org
AZD-7268 is a δ-opioid receptor agonist which was under development for the treatment of major depressive disorder but was never marketed. It is taken by mouth. The affinity (Ki) of AZD-7268 for the δ-opioid receptor was reported to be 2.7 nM and its selectivity for this receptor over the μ-opioid receptor was reported to be 2,000-fold. No animal studies of AZD-7268 appear to have been published. In addition to putative antidepressant effects, AZD-7268 might have anxiolytic effects. Structurally, AZD-7268 was derived from SNC-80. Dose-limiting side effects of AZD-7268 in clinical trials included syncope (fainting), hypotension (low blood pressure), and dizziness. AZD-7268 was first described by 2007. Its development was discontinued in 2010. It reached phase 2 clinical trials prior to the discontinuation of its development. No reason was given for the discontinuation of its development. However, the drug was found to be ineffective for major depressive disorder in a phase 2 clinical trial of 231 participants comparing it with placebo and escitalopram. The drug was under development by AstraZeneca.
=== Neurosteroid effects === Progesterone, through the actions of neurosteroid active metabolites such as allopregnanolone and pregnanolone, is a potent positive allosteric modulator of the GABAA receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). It can produce sedative, hypnotic, anxiolytic, euphoric, cognitive-, memory-, and motor-impairing, anticonvulsant, and even anesthetic effects with formation of sufficiently high concentrations of its neurosteroid metabolites and consequent GABAA receptor potentiation in the brain. These actions and effects are characteristically similar to those of other GABAA receptor positive allosteric modulators like alcohol, barbiturates, and benzodiazepines. Similarly to other GABAA receptor positive allosteric modulators like alcohol, barbiturates, and benzodiazepines, tolerance has been found to develop with exposure to increased levels of allopregnanolone and related inhibitory neurosteroids. This includes downregulation and desensitization of the GABAA receptor, reduced effects of allopregnanolone and other GABAA receptor activators (e.g., GABATooltip γ-aminobutyric acid and benzodiazepines), and rebound or withdrawal effects upon falls in allopregnanolone levels. In addition, changes in allopregnanolone levels have been implicated in adverse neuropsychiatric effects associated with the menstrual cycle (e.g., dysphoria, depression, anxiety, irritability) and postpartum period (e.g., postpartum depression), as well as in catamenial epilepsy (seizures).
October 20 – The district attorney of Westchester County announces a criminal investigation into The Trump Organization. October 21 – Rust shooting incident: Film producer Alec Baldwin fatally shoots Halyna Hutchins and wounds Joel Souza during the filming of Rust, when a prop firearm is discharged by accident. October 22 – Trump–Ukraine scandal: Former Rudy Giuliani associate Lev Parnas is convicted by the SDNY for campaign financing crimes and for illegally funding foreign cash to Republicans during the 2018 midterms. The conviction is announced by Attorney Damian Williams. October 23 – 2021 NCAA Division I FBS football season: In college football, the Illinois Fighting Illini defeats Penn State 20-18 in nine overtimes, making it the longest football game played in NCAA history. October 26 – A report comes out revealing that former Chicago Blackhawks coach Brad Aldrich sexually assaulted Kyle Beach, a young prospect on the team during the 2009–10 NHL season. The report also shows that Stan Bowman, Kevin Cheveldayoff, and Joel Quenneville met before the 2010 Stanley Cup Finals and allowed Aldrich to continue working until the end of the season. October 28 – Mark Zuckerberg announces that Facebook, Inc., owner of Facebook, Instagram, WhatsApp and Oculus, will rebrand itself as Meta Platforms. October 29 MrBeast and Mark Rober launch #TeamSeas, a project to clean up 30 million pounds of ocean trash by the end of the year. The U.S. Food and Drug Administration authorizes the emergency use of the Pfizer-BioNTech COVID-19 vaccine for children 5 through 11 years of age.
The method was developed by botanist Mikhail Tsvet in 1901–1905 in the universities of Kazan and Warsaw. He developed the technique and coined the term chromatography in the first decade of the 20th century, primarily for the separation of plant pigments such as chlorophyll, carotenes, and xanthophylls. Since these components separate in bands of different colors (green, orange, and yellow, respectively) they directly inspired the name of the technique. New types of chromatography developed during the 1930s and 1940s made the technique useful for many separation processes. Chromatography technique developed substantially as a result of the work of Archer John Porter Martin and Richard Laurence Millington Synge during the 1940s and 1950s, for which they won the 1952 Nobel Prize in Chemistry. They established the principles and basic techniques of partition chromatography, and their work encouraged the rapid development of several chromatographic methods: paper chromatography, gas chromatography, and what would become known as high-performance liquid chromatography. Since then, the technology has advanced rapidly. Researchers found that the main principles of Tsvet's chromatography could be applied in many different ways, resulting in the different varieties of chromatography described below. Advances are continually improving the technical performance of chromatography, allowing the separation of increasingly similar molecules.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.